Literature DB >> 7654701

Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

J Liu1, P Lester, S Builder, S J Shire.   

Abstract

The interaction of human IgE with high-affinity IgE Fc receptors on cells of the immune system plays an essential role in the type I hypersensitivity reaction. A proposed therapy is to use an anti-IgE monoclonal antibody to block the binding of IgE to its high-affinity receptor on mast cells and basophils, thus preventing subsequent release of the inflammatory agents after exposure to allergen. We report here the solution characteristics of immune complexes formed by a humanized anti-IgE monoclonal antibody (rhuMAb E25) and IgE using sedimentation analysis and size exclusion chromatography. We demonstrate that the rhuMAb E25 is able to form a variety of complexes with IgE at different molar ratios. The largest complex was identified by sedimentation equilibrium analysis as a heterohexamer with very high stability. The intermediate complex formed when one of the interacting components is in large molar excess appears to have a trimeric structure. The high-affinity interaction of rhuMAb E25 and IgE has also been confirmed. Furthermore, by using hydrodynamic modeling, we show that the largest complex may be represented by a cyclic structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654701     DOI: 10.1021/bi00033a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Complexation of VEGF with bevacizumab decreases VEGF clearance in rats.

Authors:  Vanessa Hsei; Geralyn G Deguzman; Alison Nixon; Jacques Gaudreault
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Is any measurement method optimal for all aggregate sizes and types?

Authors:  John S Philo
Journal:  AAPS J       Date:  2006-09-08       Impact factor: 4.009

3.  Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.

Authors:  Deborah L Mortensen; Saileta Prabhu; Eric G Stefanich; Saloumeh Kadkhodayan-Fischer; Thomas R Gelzleichter; Dana Baker; Jenny Jiang; Kristin Wallace; Suhasini Iyer; Paul J Fielder; Wendy S Putnam
Journal:  MAbs       Date:  2012 Nov-Dec       Impact factor: 5.857

Review 4.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

5.  The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody.

Authors:  J D Andya; Y F Maa; H R Costantino; P A Nguyen; N Dasovich; T D Sweeney; C C Hsu; S J Shire
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

6.  The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Authors:  Bianca Balbino; Pauline Herviou; Ophélie Godon; Julien Stackowicz; Odile Richard-Le Goff; Bruno Iannascoli; Delphine Sterlin; Sébastien Brûlé; Gael A Millot; Faith M Harris; Vera A Voronina; Kari C Nadeau; Lynn E Macdonald; Andrew J Murphy; Pierre Bruhns; Laurent L Reber
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

7.  Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

Authors:  Philip J Lowe; Stacey Tannenbaum; Aurelie Gautier; Pablo Jimenez
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 8.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

Review 9.  Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors:  Jay A Lieberman; Mirna Chehade
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 10.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.